These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28361082)

  • 1. Is the exosome a potential target for cancer immunotherapy?
    Yoshimura A; Sawada K; Kimura T
    Ann Transl Med; 2017 Mar; 5(5):117. PubMed ID: 28361082
    [No Abstract]   [Full Text] [Related]  

  • 2. Exosome Display technology: applications to the development of new diagnostics and therapeutics.
    Delcayre A; Estelles A; Sperinde J; Roulon T; Paz P; Aguilar B; Villanueva J; Khine S; Le Pecq JB
    Blood Cells Mol Dis; 2005; 35(2):158-68. PubMed ID: 16087368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-based immunotherapy.
    Chaput N; Taïeb J; Schartz NE; André F; Angevin E; Zitvogel L
    Cancer Immunol Immunother; 2004 Mar; 53(3):234-9. PubMed ID: 14727085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy.
    Moore C; Kosgodage U; Lange S; Inal JM
    Int J Cancer; 2017 Aug; 141(3):428-436. PubMed ID: 28247946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designer exosomes as next-generation cancer immunotherapy.
    Bell BM; Kirk ID; Hiltbrunner S; Gabrielsson S; Bultema JJ
    Nanomedicine; 2016 Jan; 12(1):163-9. PubMed ID: 26500074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the exosome-induced immune response for cancer immunotherapy.
    Gehrmann U; Näslund TI; Hiltbrunner S; Larssen P; Gabrielsson S
    Semin Cancer Biol; 2014 Oct; 28():58-67. PubMed ID: 24859748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.
    Xu YF; Hannafon BN; Zhao YD; Postier RG; Ding WQ
    Oncotarget; 2017 Sep; 8(44):77028-77040. PubMed ID: 29100367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosome-derived microRNAs contribute to prostate cancer chemoresistance.
    Li J; Yang X; Guan H; Mizokami A; Keller ET; Xu X; Liu X; Tan J; Hu L; Lu Y; Zhang J
    Int J Oncol; 2016 Aug; 49(2):838-46. PubMed ID: 27278879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosome-mediated miR-200b promotes colorectal cancer proliferation upon TGF-β1 exposure.
    Zhang Z; Xing T; Chen Y; Xiao J
    Biomed Pharmacother; 2018 Oct; 106():1135-1143. PubMed ID: 30119180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes as novel therapeutic nanodevices.
    Delcayre A; Le Pecq JB
    Curr Opin Mol Ther; 2006 Feb; 8(1):31-8. PubMed ID: 16506523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosome: A New Player in Translational Nanomedicine.
    Aheget H; Tristán-Manzano M; Mazini L; Cortijo-Gutierrez M; Galindo-Moreno P; Herrera C; Martin F; Marchal JA; Benabdellah K
    J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32722531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-purity capture and release of circulating exosomes using an exosome-specific dual-patterned immunofiltration (ExoDIF) device.
    Kang YT; Kim YJ; Bu J; Cho YH; Han SW; Moon BI
    Nanoscale; 2017 Sep; 9(36):13495-13505. PubMed ID: 28862274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Exosome: Trojan horse in immunotherapy].
    Mou DL; Jia ZS; Bai XF
    Sheng Li Ke Xue Jin Zhan; 2005 Apr; 36(2):113-8. PubMed ID: 16222969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z; Qiu Y; Lu W; Jiang Y; Wang J
    J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA).
    Hannafon BN; Carpenter KJ; Berry WL; Janknecht R; Dooley WC; Ding WQ
    Mol Cancer; 2015 Jul; 14():133. PubMed ID: 26178901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA.
    Morishita M; Takahashi Y; Matsumoto A; Nishikawa M; Takakura Y
    Biomaterials; 2016 Dec; 111():55-65. PubMed ID: 27723556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Exosome And Breast Cancer Cell Plasticity.
    Mao X; Jin F
    Onco Targets Ther; 2019; 12():9817-9825. PubMed ID: 31819481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes for immunotherapy of cancer.
    Chaput N; Schartz NE; Andre F; Zitvogel L
    Adv Exp Med Biol; 2003; 532():215-21. PubMed ID: 12908560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of exosome miRNAs using molecular beacons for diagnosing prostate cancer.
    Lee J; Kwon MH; Kim JA; Rhee WJ
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S52-S63. PubMed ID: 30033809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.